Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2019), 10.1007/s12094-019-02166-z)

Research output: Contribution to journalComment/debatepeer-review

Abstract

Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows: Acknowledgements FB supported by AIRC IG 20109.

Original languageEnglish
JournalClinical and Translational Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2019), 10.1007/s12094-019-02166-z)'. Together they form a unique fingerprint.

Cite this